Updated By David Poplack
(April 04, 2013)
Two novel biologic agents have shown promise in early phase clinical studies, the proteasome inhibitor bortezomib (Horton TM, Pati D, Plon SE, et al. Clin Cancer Res 2007;13:1516-22.
) and the kinase inhibitor sorafenib (which inhibits FLT3), (Widemann BC, Kim A, Fox E, ...